US FDA orders "black box" suicidality warnings and studies for Chantix and Zyban
This article was originally published in Scrip
Executive Summary
The US FDA has ordered Pfizer and GlaxoSmithKline to add "black box" label warnings about serious neuropsychiatric effects for the smoking cessation drugs Chantix (varenicline) and Zyban (bupropion). The companies also must conduct postmarketing clinical trials to determine the incidence of serious neuropsychiatric symptoms, including depression and suicidality, in patients taking the therapies.
You may also be interested in...
Chantix's Boxed Warning: Will A Positive Vote Justify A Negative Outcome?
FDA could use advisory committee members' comments to maintain the smoking cessation drug's boxed warning, even though they voted to remove it.
Removing Pfizer's Chantix Boxed Warning A One-Off, Committee Says
Advisory committee says data supports dialing back safety label for the smoking cessation product, but shouldn’t be precedent setting.
Black Triangle Warning Dropped From Pfizer's Smoking Cessation Drug Label
Europe has removed its black triangle warning from the label of Pfizer Inc.'s smoking cessation drug Champix (varenicline; known as Chantix in the US) on the back of new long-term use data.